Type | Public | |
Founded | 1923 | |
HQ | Tokyo, JP | Map |
Website | astellas.com | |
Employee Ratings | More | |
Overall Culture | F | More |
USD | |
---|---|
Revenue (Q3, 2021) | 340.6b |
Gross profit (Q3, 2021) | 318.3b |
Net income (Q3, 2021) | 60.9b |
EBITDA (Q3, 2021) | 108.6b |
EBIT (Q3, 2021) | 79.2b |
Market capitalization (16-May-2022) | 3.6t |
Closing stock price (16-May-2022) | 2.0k |
Cash (31-Dec-2021) | 350.2b |
EV | 3.3t |
USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|
Revenue | 1.3t | 1.3t | 1.3t | 1.2t |
Cost of goods sold | (229.4b) | (228.6b) | (210.3b) | (173.4b) |
Gross profit | 1.1t | 1.1t | 1.1t | 1.1t |
R&D expense | (220.8b) | (208.7b) | (224.2b) | (224.5b) |
USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 329.1b | 318.0b | 357.9b | 334.1b | 316.3b | 338.1b | 307.0b | 308.5b | 325.4b | 326.1b | 325.5b | 340.6b |
Cost of goods sold | (54.7b) | (57.0b) | (68.3b) | (53.5b) | (54.2b) | (65.6b) | (41.7b) | (42.0b) | (50.0b) | (44.1b) | (43.6b) | (47.8b) |
Gross profit | 274.4b | 261.0b | 289.7b | 285.2b | 264.8b | 280.3b | 267.6b | 268.6b | 278.2b | 282.5b | 284.4b | 318.3b |
R&D expense | (52.1b) | (47.4b) | (50.4b) | (53.5b) | (51.5b) | (54.8b) | (57.3b) | (54.4b) | (57.1b) | (58.3b) | (60.7b) | (58.6b) |
JPY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|
Cash | 328.7b | 297.5b | 313.1b | 326.1b |
Accounts Receivable | 319.5b | 342.6b | 347.0b | 343.2b |
Prepaid Expenses | 9.1b | 12.7b | 11.5b | |
Inventories | 147.6b | 151.5b | 151.0b | 164.1b |
JPY | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 309.7b | 306.9b | 331.3b | 259.4b | 311.4b | 277.6b | 239.9b | 286.7b | 306.5b | 301.9b | 318.3b | 350.2b |
Accounts Receivable | 333.5b | 323.1b | 347.1b | 358.8b | 335.8b | 366.9b | 360.7b | 332.7b | 345.6b | 364.2b | 357.8b | 373.9b |
Inventories | 145.6b | 149.1b | 145.2b | 150.5b | 148.0b | 149.3b | 155.1b | 155.7b | 155.7b | 157.3b | 148.7b | 151.6b |
JPY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|
Net Income | 218.1b | 249.0b | 245.4b | 145.3b |
Depreciation and Amortization | 64.9b | 63.5b | 66.4b | 72.7b |
Inventories | 37.8b | (5.5b) | (6.0b) | (2.3b) |
Accounts Payable | (43.8b) | 40.8b | (21.4b) | (51.6b) |
JPY | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 64.5b | 128.3b | 212.8b | 76.5b | 161.6b | 239.2b | 60.2b | 89.1b | 164.2b | 35.8b | 89.1b | 167.4b |
Depreciation and Amortization | 16.1b | 31.8b | 47.8b | 17.0b | 31.1b | 48.3b | 18.0b | 35.9b | 54.1b | 18.1b | 37.1b | 58.6b |
Inventories | 2.4b | 3.6b | 2.0b | (3.5b) | (4.6b) | (988.0m) | (3.2b) | (2.9b) | (1.5b) | 8.3b | 15.4b | 17.3b |
Accounts Payable | (5.9b) | (11.4b) | 44.6b | (45.0b) | (24.5b) | (42.7b) | (30.2b) | (50.8b) | (59.2b) | (13.2b) | (8.8b) | 1.1b |
USD | FY, 2018 |
---|---|
Revenue/Employee | 78.3m |
Company Name | Date | Deal Size |
---|---|---|
Iota Biosciences | October 15, 2020 | $127.5 m |
Nanna Therapeutics | April 21, 2020 | £12 m |
Xyphos | December 26, 2019 | |
Audentes Therapeutics | December 02, 2019 | $3 b |
Potenza Therapeutics | December 14, 2018 | $405 m |
Quethera | August 14, 2018 | £85 m |
Universal Cells Inc. | February 13, 2018 | |
Mitobridge | December 01, 2017 | |
Ogeda | April 02, 2017 | €500 m |
Ganymed Pharmaceuticals | October 28, 2016 | $1.4 b |
Astellas Pharma revenue breakdown by business segment: 36.7% from XTANDI, 13.1% from BETANIS/MYRBETRIQ/BETMIGA, 35.6% from OTHER NONDISCLOSED and 14.6% from PROGRAF
Astellas Pharma revenue breakdown by geographic segment: 22.3% from Japan, 23.5% from Established Markets, 8.9% from International, 37.9% from United States and 7.4% from Other
Astellas Pharma has 50.39k Twitter Followers. The number of followers has increased 0.6% month over month and increased 2.6% quarter over quarter
4.4k
Tweets
1.3k
Following
50.4k
Followers
25
Tweets last 30 days
5.8
Avg. likes per Tweet
96%
Tweets with engagement
F
34/100
F
30/100
F
10/100
When was Astellas Pharma founded?
Astellas Pharma was founded in 1923.
Who are Astellas Pharma key executives?
Astellas Pharma's key executives are Kenji Yasukawa, Naoki Okamura and Fumiaki Sakurai.
How many employees does Astellas Pharma have?
Astellas Pharma has 15,455 employees.
What is Astellas Pharma revenue?
Latest Astellas Pharma annual revenue is $1.2 t.
What is Astellas Pharma revenue per employee?
Latest Astellas Pharma revenue per employee is $80.8 m.
Who are Astellas Pharma competitors?
Competitors of Astellas Pharma include Shionogi, Nipro Corporation and Hetero.
Where is Astellas Pharma headquarters?
Astellas Pharma headquarters is located at 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo.
Where are Astellas Pharma offices?
Astellas Pharma has offices in Tokyo, Takahagi, Takaoka, Toyama and in 56 other locations.
How many offices does Astellas Pharma have?
Astellas Pharma has 63 offices.
Receive alerts for 300+ data fields across thousands of companies